Envision Pharma Group, which is backed by Halifax, said Wednesday that it has acquired ProScribe. No financial terms were disclosed. Based in Queensland, Australia, ProScribe is a medical writing company.
Washington, DC and Horsham, UK, February 5, 2014 – Envision Pharma Group, a global technology and scientific communication company, announced today that it has acquired Queensland, Australia-based ProScribe, a medical writing company. The acquisition will be Envision’s first in the Asia-Pacific region. Terms of the transaction were not disclosed. The Halifax Group (“Halifax”), a leading private equity firm, initially partnered with Envision Pharma and its management team in June 2013.
ProScribe is a specialty medical writing company with offices in Australia, China and Japan, providing services to academia, biopharma, and medical device companies . ProScribe takes a leadership role in championing the need for ethical, transparent data dissemination within the Asia-Pacific region and beyond.
Envision Pharma is focused on the pharmaceutical, biotechnology and medical device industries. Along with Envision, Evidence, Excel and Engage, ProScribe will operate as the fifth Scientific Solutions division within the Envision Pharma Group. ProScribe founders Professor Karen Woolley and Dr. Mark Woolley will join the senior management team of Envision and continue to lead ProScribe’s dedicated team of medical writers, all of whom are exceptionally well versed in the complex, and often culturally sensitive, environment in which they operate.
Envision co-founder Brian Hepburn remarked, “We are pleased to partner with Professor and Dr. Woolley and their outstanding team. The addition of ProScribe expands our presence and capability within the Asia-Pacific region, and in concert with our existing offices, gives the Envision Pharma Group dedicated resources on three continents, enabling us to provide a truly global service that mirrors our clients’ needs in today’s environment.”
“We found the right partner in EnvisionPharma. The synergy between ProScribe and Envision means that we have created an industry-leading global service group that is unrivalled in terms of scientific knowledge and expertise, regulatory and compliance understanding, ethical publication practices, and industry insight,” commented Professor Woolley.
Halifax principal Scott Plumridge added, “We fully appreciate the global nature of the pharmaceutical and biotechnology industry and the strategic importance of the Asia-Pacific region. ProScribe’s talented team has developed an enviable position within the scientific communications market, and we are thrilled to have them join the Envision platform.”
About Envision Pharma
Founded in 2001, Envision Pharma Group is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Envision offers a unique blend of solutions including strategic publication planning and related data dissemination and consultancy services, enhanced with industry-leading complementary technology solutions. Envision has 5 offices, 2 in the United Kingdom and 3 in the United States. The company now has over 300 team members, including over 145 highly qualified and experienced in-house medical writers and a 55-strong technology solutions team providing platform development and customer support. Envision continues today under the stewardship of the core management team that formed the company in 2001.
About The Halifax Group
The Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and grow lower middle-market businesses across a variety of industries including health and wellness, infrastructure, business and government services and franchising. The firm maintains offices in Washington, D.C.; Dallas, TX; and Raleigh, NC. For more information, please visit www.thehalifaxgroup.com.